Sabby Management’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Sabby Management’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,331	Closed	-$99.4K	–	135
2022 Q4	$99.4K	Buy	+18,331	New	+$147K	0.09%	72
2022 Q2	–	Sell	-3,559	Closed	-$91K	–	154
2022 Q1	$91K	Sell	3,559 -17,274	-83%	-$511K	0.01%	118
2021 Q4	$956K	Buy	20,833 +4,896	+31%	+$334K	0.14%	84
2021 Q3	$1.47M	Sell	15,937 -747	-4%	-$77.3K	0.2%	70
2021 Q2	$2.41M	Buy	+16,684	New	+$4.18M	0.34%	42

Other funds holding KRBP

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's KRBP Position: Q1 2023 in Review

Sabby Management sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q1 2023, closing a stake of 18,331 shares — an estimated $99.4K sold.

Sabby Management first reported a position in KRBP in Q2 2021 and held it in 5 quarters. The position peaked at $2.41M in Q2 2021. 7 funds tracked by Wall St. Rank hold KRBP as of Q1 2023.

Sabby Management reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Sabby Management sold 18,331 Kiromic BioPharma, Inc. Common Stock shares in Q1 2023, an estimated $99.4K.
Sabby Management first reported a position in Kiromic BioPharma, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Sabby Management's Kiromic BioPharma, Inc. Common Stock position peaked at $2.41M in Q2 2021.
7 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.